Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
9 pending office actions • 9 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
The University of Sydney has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 distinct examiners and 9 distinct art units, showing that the current prosecution workload is broadly distributed across examination channels.
LIPPERT, JOHN WILLIAM is the busiest examiner, with 1 pending matter. No examiner carries multiple pending matters, so docket control, response consistency, and matter-specific technical analysis are central management needs. The broad art-unit spread also limits reliance on a single recurring examination approach.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (56%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 1 | 59.2% | +39.9% |
| HOUSHMAND, HOOMAN | 1 | 55.2% | +23.6% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| FELTON, AILEEN BAKER | 1 | 51.7% | +16.7% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| CONTRERAS, CIEL P | 1 | 54.3% | +33.6% |
| MARTIN, RACHEL E | 1 | 54.2% | +54.0% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691422 | WIRELESS COMMUNICATION PROTOCOL | HOUSHMAND, HOOMAN | — |
| 18453027 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COPPINS, JANET L | — |
| 18248167 | PLASMA ASSISTED ELECTROCATALYTIC CONVERSION | CONTRERAS, CIEL P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | REYNOLDS, FRED H | 85d overdue |
| 17594994 | METHODS FOR THE FRACTIONATION OF PROTEINS | MARTIN, RACHEL E | 1d overdue |
| 18441515 | ANTI-CANCER COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 9d |
| 18532759 | CHEMICAL INHIBITORS FOR HIGH TEMPERATURE AND REACTIVE GROUND | FELTON, AILEEN BAKER | 36d |
| 18844576 | IN VIVO TRANSITION METAL DETECTION | LIPPERT, JOHN WILLIAM | — |
| 18691422 | WIRELESS COMMUNICATION PROTOCOL | HOUSHMAND, HOOMAN | — |
| 18453027 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COPPINS, JANET L | — |
| 18248167 | PLASMA ASSISTED ELECTROCATALYTIC CONVERSION | CONTRERAS, CIEL P | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 2429 | 1 |
| 1621 | 1 |
| 1734 | 1 |
| 1628 | 1 |
| 1618 | 1 |
| 1794 | 1 |
| 1657 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844576 | IN VIVO TRANSITION METAL DETECTION | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18691422 | WIRELESS COMMUNICATION PROTOCOL | HOUSHMAND, HOOMAN | 2429 | §102§103§112 | Final Rejection | — | Pending | Mar 12, 2024 |
| 18441515 | ANTI-CANCER COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Final Rejection | 9d | Pending | Feb 14, 2024 |
| 18532759 | CHEMICAL INHIBITORS FOR HIGH TEMPERATURE AND REACTIVE GROUND | FELTON, AILEEN BAKER | 1734 | §103 | Non-Final OA | 36d | Pending | Dec 07, 2023 |
| 18453027 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COPPINS, JANET L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18258394 | LIGANDS AND THEIR USE | BAEK, JONGHWAN NMN | 1618 | §103 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18248167 | PLASMA ASSISTED ELECTROCATALYTIC CONVERSION | CONTRERAS, CIEL P | 1794 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17594994 | METHODS FOR THE FRACTIONATION OF PROTEINS | MARTIN, RACHEL E | 1657 | §103 | Final Rejection | 1d overdue | Pending | Nov 04, 2021 |
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 85d overdue | Pending | Nov 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe University of Sydney has 9 pending office actions as of October 2026, spread across 9 art units and 9 examiners.
John William Lippert has the most, with 1 of The University of Sydney's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
